Aegerion discloses DoJ subpoena, announces preliminary 2013 sales, 2014 outlook

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion (AEGR) shares plunge 10.6% AH after the company couches a disclosure that it has received a subpoena from the DoJ requesting documents regarding its marketing/sales of JUXTAPID in a preliminary sales results PR.

The company announces preliminary 2013 sales of $48M-$49M vs. consensus of $49.8M.

The company sees sales of $190M-$210M in 2014 vs. consensus of $204.2M with opex of $185M-$195M. Aegerion expects to be cash flow positive by 2H 2014.